Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer
{{output}}
Background Bevacizumab (Bev) is generally well-tolerated, and Bev-associated intestinal perforation (BAP) is a rare albeit serious side effect in cases of non-small cell lung cancer (NSCLC). Therefore, the present study aimed to identify clinical predictors of... ...
